Drug-Delivery System for Prevention and Treatment of Autoimmune Diseases Including Type 1 Diabetes

Technology #13603

Targets Drug Delivery Particles to Specific Antigen Presenting Cells for an Effective Immune Response

This drug-delivery system prevents and treats Type 1 diabetes and other autoimmune diseases, such as rheumatoid arthritis, lupus and multiple sclerosis. Autoimmune diseases cause the body to attack its own cells, tissues and organs. In the United States 15 million to 24 million people, about 8 percent of the population, have autoimmune diseases. These diseases typically result from a combination of genetic and environmental factors, which have been difficult targets of conventional drug monotherapies. Researchers from the University of Florida have invented a multi-component, microparticle-based drug-delivery system that couples principles of conventional vaccines with distinct drug-delivery systems to elicit protective immunity in cancer and infection, or immune tolerance in autoimmunity, allergy, and transplantation. This approach is founded on the use of biodegradable biomaterials that provide targeted, controlled co-delivery of antigen and immunomodulatory factors to critical cell types of the immune system. Diabetes, the principal application for the technology, affects more than 25 million Americans, 10 percent of whom have Type 1 diabetes. Diabetes is a lifelong and chronic disease in which the body cannot process sugar, according to the American Diabetes Association. In 2007, the total cost of diabetes in the U.S. was approximately $218 billion.


A drug-delivery system for the prevention and treatment of autoimmune diseases, such as Type 1 diabetes, allergies and transplant rejection


  • Prevents the onset of autoimmune diseases, such as Type 1 diabetes, saving time and costly medical expenses
  • Contains therapeutic applications that reduce adverse reactions, allowing for improved patient comfort
  • Is a first-in-class drug-delivery platform, providing a competitive advantage
  • Is modular in nature, providing a platform technology for a wide array of autoimmune conditions including systemic lupus erythmatosus, Sjogren’s syndrome, rheumatoid arthritis, and allergies, allowing for multiple market opportunities


The drug-delivery system consists of an injectable microparticle-based system that contains immunomodulatory factors that attract and provide tolerance conditioning to immune cells, such as dendritic and T-cells, at the site of the injection. The system can deliver various antigens and immune modifying factors. This system may also be useful in the treatment of other autoimmune diseases, allergies and transplantation.